| http://purl.uniprot.org/citations/37551683 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/37551683 | http://www.w3.org/2000/01/rdf-schema#comment | "Purpose: Previous studies of MMP-3 -1171 5A/6A in cancers have produced inconclusive outcomes. This updated meta-analysis was performed to clarify the link between this variant and cancer. Methods: Databases including PubMed, Google Scholar, EMBASE and Cochrane were searched for data collection. The associations were calculated by odds ratios with 95% CIs. Results: 63 eligible studies with 14,252 cases and 15,176 controls were included. The codominant 2, codominant 3, dominant, recessive and allele models were found to be significantly associated with 1.28-, 1.13-, 1.13-, 1.19- and 1.13-fold enhanced overall risk of cancer, respectively. Stratification analysis revealed a 1.28-times enhanced risk of esophageal cancer (codominant 1), 1.29- and 1.26-fold (codominant 3) and 1.18- and 1.28-fold (recessive model) enhanced risk in colorectal and gastrointestinal cancers, respectively, 1.30-, 1.35- and 1.22-times in codominant model 1, dominant and allele models for breast cancer, 1.56-fold (codominant 2) for gynecological cancer and 2.40-times in codominant model 2 for hepatocellular cancer. Conclusion: This meta-analysis suggests a significant association between the MMP-3 -1171 5A/6A variant and cancer. This meta-analysis was registered at INPLASY (registration number: INPLASY202280049)."xsd:string |
| http://purl.uniprot.org/citations/37551683 | http://purl.org/dc/terms/identifier | "doi:10.2217/fon-2022-1306"xsd:string |
| http://purl.uniprot.org/citations/37551683 | http://purl.uniprot.org/core/author | "Islam M.S."xsd:string |
| http://purl.uniprot.org/citations/37551683 | http://purl.uniprot.org/core/author | "Aziz M.A."xsd:string |
| http://purl.uniprot.org/citations/37551683 | http://purl.uniprot.org/core/author | "Anonna S.N."xsd:string |
| http://purl.uniprot.org/citations/37551683 | http://purl.uniprot.org/core/author | "Jafrin S."xsd:string |
| http://purl.uniprot.org/citations/37551683 | http://purl.uniprot.org/core/author | "Barek M.A."xsd:string |
| http://purl.uniprot.org/citations/37551683 | http://purl.uniprot.org/core/date | "2023"xsd:gYear |
| http://purl.uniprot.org/citations/37551683 | http://purl.uniprot.org/core/name | "Future Oncol"xsd:string |
| http://purl.uniprot.org/citations/37551683 | http://purl.uniprot.org/core/pages | "1495-1512"xsd:string |
| http://purl.uniprot.org/citations/37551683 | http://purl.uniprot.org/core/title | "pii>MMP-3pi/i> -1171 5A/6A promoter polymorphism and cancer susceptibility: an updated meta-analysis and trial sequential analysis."xsd:string |
| http://purl.uniprot.org/citations/37551683 | http://purl.uniprot.org/core/volume | "19"xsd:string |
| http://purl.uniprot.org/citations/37551683 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/37551683 |
| http://purl.uniprot.org/citations/37551683 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/37551683 |
| http://purl.uniprot.org/uniprot/#_A0A0U3J4I2-mappedCitation-37551683 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/37551683 |
| http://purl.uniprot.org/uniprot/#_A5GZ70-mappedCitation-37551683 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/37551683 |
| http://purl.uniprot.org/uniprot/#_P08254-mappedCitation-37551683 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/37551683 |
| http://purl.uniprot.org/uniprot/A5GZ70 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/37551683 |
| http://purl.uniprot.org/uniprot/A0A0U3J4I2 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/37551683 |
| http://purl.uniprot.org/uniprot/P08254 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/37551683 |